表柔比星联合紫杉醇治疗三阴性乳腺癌效果分析

Analysis of the efficacy of pirarubicin combined with paclitaxel in the treatment of three negative breast cancer

目的研究分析柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果。方法选取山西省肿瘤医院2014年1月~2016年12月收治的100例三阴性乳腺癌患者为研究对象,随机分为对照组和实验组2组,每组患者各为50例。对照组给予表柔比星治疗,实验组患者表柔比星联合紫杉醇治疗。比较分析实验组与对照组的近期缓解率、Karnofsky评分以及不良反应发生情况。结果经过对应的治疗后,实验组患者Karnofsky评分为（89.76±10.12）分,对照组患者Karnofsky评分为（71.23±11.67）分。可得,实验组患者的Karnofsky评分显著高于对照组患者,差异具有统计学意义（P〈0.05）。实验组患者近期缓解例数为44例,近期缓解率为88.0%,对照组患者近期缓解率为72.0%。可得,实验组患者近期缓解率显著高于对照组患者,差异具有统计学意义（P〈0.05）。经过治疗后,对照组与实验组患者发生并发症概率差异无统计学意义。结论表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果较好,能够在很大程度上提高近期缓解率,提高患者生活质量,具有临床进一步推广和应用的意义。

Objective To study the clinical efficacy of epirubicin combined with paclitaxel in the treatment of three negative breast cancer.Methods 100 patients with breast cancer who were treated in Shanxi Cancer Hospital from January 2014 to December 2016 were selected as the research object in this study. They were randomly divided into the control group and the experimental group,with each group having a total of 50 patients. The control group was treated with epirubicin,and the experimental group was treated with epirubicin combined with paclitaxel. The short-term remission rate,Karnofsky score and the incidence of adverse symptoms were compared between the experimental group and the control group. Results After treatment,the Karnofsky score of the experimental group was（ 89. 76 ± 10. 12）,and the Karnofsky score of the control group was（ 71. 23 ± 11. 67）. The Karnofsky score of the experimental group was significantly higher than that of the control group（ P〈 0. 05）. In the experimental group,the number of short-term remission was 44 cases,the short-term remission rate was 88. 0%,and the number of patients in the control group in the recent remission was in the number of cases,the short-term remission rate was 72. 0%,and the number of patients in the control group was about 36. The results showed that the short-term remission rate of the experimental group was significantly higher than that of the control group,with statistical difference（ P 〈0. 05）. After treatment,there was no significant difference between the control group and the experimental group in the incidence of complications,which was not statistically significant. Conclusion The clinical effect of doxorubicin plus paclitaxel in the treatment of three negative breast cancer,can improve the remission rate in a large extent,improve the quality of life of patients,with further clinical promotion and application significance.